MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM
NCT ID: NCT06171685
Last Updated: 2025-07-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
300 participants
INTERVENTIONAL
2024-11-17
2030-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Horizon Two Adaptive Platform Study in High Risk Newly Diagnosed Multiple Myeloma
NCT07053436
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
NCT04722146
A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
NCT06151717
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
NCT06106945
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NCT00461045
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sub-protocol A
Serves as the reference arm for the platform
Teclistamab Monotherapy
standard of care
Sub-Protocol B
This arm will be an investigational arm
Teclistamab
investigational doses compared to SOC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Teclistamab Monotherapy
standard of care
Teclistamab
investigational doses compared to SOC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ≥18 years of age
* Histologically confirmed multiple myeloma that is exposed, relapsed, or intolerant to one of each of the following classes of agents:
* A proteasome inhibitor
* An immunomodulatory drug
* An anti-CD38-monoclonal antibody
* Must have received between 1-4 lines of prior systemic therapy
* Prior BCMA-directed antibody-drug conjugate (ADC) or chimeric antigen receptor (CAR)-T cell therapy allowed Note: A washout period of 6 months is required from prior anti-BCMA therapy. For BCMA CAR-T cell therapy, participants must be ≥ 6 months from lymphodepleting chemotherapy.
* Measurable disease, defined as one of the following:
* M-protein ≥ 0.50g/dL (0.5 g/dL or above if IgA subtype)
* Urine M-protein (Bence-Jones protein) ≥ 200 mg/24hours
* Serum free light chain difference \> 100 mg/L
* Biopsy proven plasmacytoma
* For oligosecretory multiple myeloma, disease must be measurable by imaging (i.e., PET-CT, MRI)
* ECOG performance status of 0-2
* Adequate organ function, as indicated by the following laboratory values:
* Adequate hematological function, defined as ANC ≥ 1000/µL, platelet count ≥ 50,000/µL, and hemoglobin ≥ 8 g/dL (transfusion and/or growth factor support is allowed for hematologic parameters as long as the investigator deems the participant otherwise fit for screening)
* Adequate hepatic function, defined as total bilirubin level \< 1.5 x institutional upper limit of normal (IULN) (except in participants with congenital bilirubinemia, such as Gilbert syndrome, in which case direct bilirubin \< 1.5-3.0 x IULN is required), AST ≤ 2.5 x IULN, and ALT ≤ 2.5 x IULN
* Adequate renal function, defined as calculated creatinine clearance ≥ 30 mL/min per institutional standard (assessment method should be recorded, measured or C-G acceptable)
* eGFR \> 30mL/min based on MDRD 4-variable formula calculation or creatinine clearance based measured by 24h urine collection
* Corrected serum calcium \<14mg/dL or free ionized calcium \<6.5 mg/dL
* Persons of childbearing potential must have a negative serum pregnancy test at screening (within 72 hours of first dose of trial medication). Non-childbearing potential for a person assigned as female at birth is defined as 1 of the following:
* ≥ 45 years of age and has not had menses for \>1 year
* Amenorrheic for \> 2 years without a hysterectomy and/or oophorectomy and follicle-stimulating hormone value in the postmenopausal range upon pretrial (screening) evaluation
* Status is post-hysterectomy, -oophorectomy, or -tubal ligation
* Persons of childbearing potential must be willing to use highly effective contraceptive measures during sexual contact with a person assigned as male at birth starting with the Screening visit through 90 days after last dose of trial medication.
Note: Abstinence is acceptable if this is the established and preferred contraception for the participant.
-Persons assigned as male at birth with a partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the trial starting with the Screening visit through 90 days after the last dose of trial medication is received. Persons assigned as male at birth with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
Note: Abstinence is acceptable if this is the established and preferred contraception method for the participant.
* Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using New York Heart Association Functional Classification. To be eligible for this trial, participants should be Class 2 or better. Class 2 is defined as slight limitation of physical activity, in which ordinary physical activity leads to fatigue, palpitation, or dyspnea; the person is comfortable at rest.
* Prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of the investigational arms are eligible for this trial.
* Known HIV infection who are on effective anti-retroviral therapy with undetectable viral load within 6 months of screening and enrollment are eligible for this trial.
* Evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated.
* History of hepatitis C virus (HCV) infection must have been treated and cured. For participants with known HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
* Willing and able to comply with the requirements of the protocol.
Exclusion Criteria
* Major concurrent illness or organ dysfunction including but not limited to the following:
* Plasma cell leukemia (the presence of ≥ 5% circulating plasma cells in peripheral blood smears)
* Waldenström's macroglobulinemia
* POEMS syndrome
* Primary amyloid light-chain amyloidosis
* History of allergy or known hypersensitivity to any of the trial therapies or any of their excipients, or contraindication to any of the trial therapies as outlined in the local prescribing information (e.g., United States Prescribing Information \[USPI\]).
* Complete cord compression or CNS involvement
* Active or history of autoimmune disease that requires systemic treatment within 2 years of the start of study drug (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs).
Note: Participants with diabetes type 1, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
* Received a live, attenuated vaccine within 4 weeks before the first dose of study drug. Non-live or nonreplicating vaccines authorized for emergency use (eg, COVID-19) by local health authorities are allowed.
* Allogeneic tissue/solid organ transplant recipients with chronic GVHD requiring steroid equivalent dose of \> 20 mg prednisone
* Active infection requiring treatment
* History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator
* Psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
* Legally incapacitated or has limited legal capacity
* Persons who are pregnant or lactating
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Multiple Myeloma Research Consortium
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hearn J Cho, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Multiple Myeloma Research Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Emory Winship Cancer Center
Atlanta, Georgia, United States
University of Chicago Cancer Center
Chicago, Illinois, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute/Harvard Medical School
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Center
Detroit, Michigan, United States
Mayo Clinic Rochester
Rochester, Minnesota, United States
Washington University Medicine
St Louis, Missouri, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Mt. Sinai School of Medicine
New York, New York, United States
Atrium Levine Cancer Institute
Charlotte, North Carolina, United States
Tennessee Oncology
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MMRC-099
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.